Navigation Links
Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
Date:4/21/2011

>
  • Additionally, Valeant's stated 24% premium to Cephalon's closing price as of March 29, 2011 is significantly below the 59% 30-day and 48% 1-day median acquisition premium for U.S. life-science acquisitions since 2006.  Valeant's 0.4% premium to Cephalon's 52-week high between March 29, 2010 and March 29, 2011 of $72.87, is also far below the median 20% premium to 52-week highs of U.S. life-science acquisitions since 2006.(1)

  • As a Bloomberg article recently noted, "The $73 a share bid valued the transaction at $5.46 billion including net debt, data compiled by Bloomberg show. At that price, the deal is 5.3 times Cephalon's trailing EBITDA of $1.04 billion last year, the data show. That's 65 percent lower than the median 15.1 times for all drug takeovers over $1 billion."(2)

    Cephalon has created a broad pipeline, with 10 late-stage product candidates targeted at novel and "best-in-class" therapeutics.(3)  Your Board and management team have a proven history of developing late-stage compounds such as PROVIGIL, NUVIGIL, FENTORA and TREANDA, among others.  Your Board believes these programs represent significant value that is not reflected in Valeant's $73 per share proposal, but which Valeant would seek to capture for itself either on its own or through transactions with third parties.

    As Valeant's CEO has publicly stated, Valeant is estimating synergies of $300 million in the proposed transaction with Cephalon.  In Valeant's 2010 merger with Biovail, Valeant initially announced $175 million of synergies but ultimately identified synergies in excess of $300 million, or almost double its estimate.  If this pattern holds true, Valeant's synergies in a Cephalon transaction could greatly exceed Valeant's predictions.  These incremental synergies are indicative of the value that Valeant would like to keep fully for its shareholders by paying an inadequate price to Cephalon shareholders.

    Valeant is also impo
    '/>"/>

    SOURCE Cephalon, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cephalon Quarterly Conference Call Invitation
    2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
    3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
    4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
    5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
    6. Cephalon Reports Another Strong Quarter
    7. Cephalon, Inc. to Webcast Analyst Day
    8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
    9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
    10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
    11. Cephalons New Product Launches Pace Record 2008 Sales
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... be presenting at the Baird Healthcare Conference in New ... Chief Financial Officer, will be making a presentation on ... on Wednesday, Sept. 3, 2014. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
    (Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
    (Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
    (Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
    Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
    ... , , , ... the Sciences in Education over the Next Decade , WASHINGTON, Dec. ... continuously published magazine in the U.S., hosted The Decade-2 ... to promote the teaching of math and science to America,s students and was ...
    ... , , PROVIDENCE, R.I., Dec. 9 The ... disease (AD), which was conducted at 30 sites around the ... Neurology®. Lead author, Stephen P. Salloway, MD, MS, director ... professor of neurology and psychiatry at the Warren Alpert Medical ...
    ... , SAN DIEGO, Dec. 9 Sangart, Inc., a ... designed to enhance the perfusion and oxygenation of ischemic ... delivery, today announced that the European Commission (EC) has ... treatment of sickle cell disease. This designation provides ten ...
    Cached Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3
    (Date:8/21/2014)... ignore, but they are the ultimate source of all ... increasingly dependent on algae, too, to suck up climate-warming ... the bottom of the ocean. Now, by using a ... evidence showing that viruses infecting those algae are driving ... all else stays essentially the same, and this has ...
    (Date:8/21/2014)... the food intake, health and quality of life of ... projects at the University of Waterloo receiving close to ... Health Research (CIHR). , Professor Heather Keller, of ... a Schlegel research chair in nutrition and aging, will ... Canadians living in long-term care homes are poorly nourished. ...
    (Date:8/21/2014)... is a key region in the global oceanic circulation. "On ... warm Atlantic water flows to the north into the Arctic ... and sea ice push their way out of the Arctic ... water cools here on its way to the north and ... in this manner drives the global band of oceanic currents ...
    Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2Grants will fund landmark aging research at Waterloo 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
    ... cause poor lung development in children, making them more vulnerable ... in life, say researchers at the University of Pittsburgh Graduate ... Environmental Health. Their study, published online in Physiological Genomics ... in both mouse lungs and children ages 9 to 11. ...
    ... with the flu virus, we have investigated how the ... of the Experimental Mouse Genetics research group. In infection ... immune response is responsible for the fatal outcome of ... The findings have now been published in the scientific ...
    ... 2009 A material developed at the Hebrew University ... tissue) following surgery has led to approval by the ... for use in pediatric cardiac surgery patients. ... invention of novel, tailor-made, biodegradable polymers for the prevention ...
    Cached Biology News:Changes in gene may stunt lung development in children 2The host makes all the difference 2Hebrew University professor's work leads to FDA approval for product 2
    QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Antibody Diluent for IHC 125 ml...
    Quinolinate phosphoribosyltransferase...
    JMJD2B Antibody...
    Biology Products: